• news-banner

    Expert Insights

COVID-19: Advertising Responsibly

The ASA continues its drive to ensure responsible advertising during the COVID-19 pandemic.

At the outset of the pandemic the ASA took swift action to highlight to advertisers it would act quickly and robustly against ads that exploited people’s health related anxieties and the difficult financial or employment circumstances many people were facing. The ASA also published guidance on the main areas in which it believed ads may be deemed problematic. Despite this there have been a number of ads which have fallen foul of the CAP Code.

The latest series of problematic ads related to a vitamin C drink containing claims such as “Vitamin-C has been proven to boost immunity” which, taken in the midst of the pandemic, could be taken to imply that the drink could help to prevent, treat or cure COVID-19. Making such claims is not permitted unless the products in question are authorised on the EU Register of nutrition and health claims, which this product was not. It is also prohibited to make claims that food and supplements can prevent, treat or cure human disease. The ASA therefore held that the ads must not appear again.

Below we have outlined the ASA guidance and rulings since the beginning of the pandemic to highlight the main areas of concern which may have the potential to grossly undermine the UK’s response to the pandemic.

Key Areas of concern and ASA Rulings

1. Medicines and medical devices:

The key issue in this space is that ‘medical or medicinal claims’ can only be made for products where they are licenced medicines or appropriately marked medical devices.

ASA Rulings:

  • The ASA banned an ad which promoted an “Anti-Corona Virus Face Mask”.
  • The ASA banned a series of ads which promoted a “New Nano Tech Face Mask” and implied that the mask would offer protection against being infected by COVID-19.

2. Alternative and complementary therapies

The ASA made clear that it was likely to consider COVID-19 a condition for which medical supervision should be sought.

ASA Rulings:

  • The ASA banned advertising claims on websites and in social media made by three clinics offering IV drip treatments which made medicinal claims that implied they could prevent or treat COVID-19.

3. Food or food supplements

As seen above, the ASA made clear that ads that make health related claims and/or suggest a product may help protect consumers from infection of COIVD-19 by, for example, supporting their immune system, were likely to be viewed as problematic.

4. Fear, distress and social responsibility

The ASA highlighted that ads should not exploit an audience’s fear in order to mislead them into buying a product.

ASA Rulings:

  • The ASA banned an ad which stated “British Build, beds proudly made in the UK. No Nasty imports”. The ad also contained imagery whereby a cartoon mattress was wearing a green surgical mask. In the ASA’s view the ad was likely to cause serious or widespread offence as in combination with the image the reference to “nasty imports” was likely to be read as a negative reference to immigration or race.

Moving Forward

Ads in any of the special interest areas above will likely receive additional scrutiny from both the public and regulators. Advertisers must exercise special caution and be mindful of how ads may be perceived by the public in the current heightened state of awareness, especially if those ads contain health-related claims.
For more information on any of the ASA Rulings set out above, please use the following link

Our thinking

  • IBA Annual Conference 2023

    Charlotte Ford


  • Mental Health Management

    Nick Hurley


  • Charles Russell Speechlys expands presence in Greater China with the arrival of Litigation and Dispute Resolution Partner Stephen Chan

    Stephen Chan


  • Family and Employment law assistance in legal advice deserts

    Sarah Farrelly


  • Property Patter: the latest on the Building Safety Act

    Richard Flenley


  • James Souter writes for City AM on Meta pulling out of its London office

    James Souter

    In the Press

  • Charles Russell Speechlys advises Puma Private Equity on its £3.5 million investment into TravelLocal

    David Coates


  • The Evening Standard quotes Rose Carey on the increase in visa fees

    Rose Carey

    In the Press

  • Charles Russell Speechlys advises Zenzero’s management team on its majority acquisition by Macquarie Capital

    Mark Howard


  • David Savage writes for Construction News on the upcoming building-control overhaul

    David Savage

    In the Press

  • Updates and points to note in relation to buy-to-let residential properties

    Twiggy Ho


  • Felicity Chapman writes for Insider Media on alternatives to court for divorcing business owners

    Felicity Chapman

    In the Press

  • Investment Week quotes Julia Cox on the proposed scrapping of inheritance tax

    Julia Cox

    In the Press

  • Charles Russell Speechlys expands commercial offering with the appointment of Rebecca Steer

    Rebecca Steer


  • The Times quotes Gareth Mills on the CMA’s preliminary approval of the Activision Blizzard-Microsoft deal

    Gareth Mills

    In the Press

  • Heritage property and conditional exemption

    Sarah Wray


  • Property Week quotes Cara Imbrailo on Rishi Sunak scrapping MEES requirements for residential landlords

    Cara Imbrailo

    In the Press

  • The Financial Times quotes Emma Humphreys on UK rental costs

    Emma Humphreys

    In the Press

  • City AM quotes Gareth Mills on the CMA’s new set of principles for regulating AI

    Gareth Mills

    In the Press

  • Hamish Perry and Mike Barrington write for The Evening Standard on whether a merger between the CBI and Make UK can work

    Hamish Perry

    In the Press

Back to top